ABBVvsAMGN
AbbVie IncvsAmgen Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.
AbbVie Inc
$205.12
-11.14%
Amgen Inc
$348.62
+6.70%
60-day price, rebased to 100
Round-by-round
Valuation upside
-49.60% vs -41.60% to DCF fair value
Balance-sheet strength
Altman Z 2.25 vs 1.78
Fundamental quality
Piotroski 7.00 vs 8.00 (of 9)
Growth + margins
Rule-of-40 37.70 vs 32.00
60-day momentum
-9.10% vs +1.97% price return
Market-cap liquidity
$362.8B vs $188.8B
Verdict
Across6categories,the two names are evenly matched —3wins each. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.
Backtest a strategy onABBVorAMGN
Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.